Catalent Pharma Solutions, Inc. (CTLT)
| Market Cap | 11.52B |
| Revenue (ttm) | 1.81B +2.3% |
| Net Income | 8.20M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,674,041 |
| Open | 63.49 |
| Previous Close | 63.48 |
| Day's Range | 63.44 - 63.50 |
| 52-Week Range | 42.07 - 63.50 |
| Beta | 1.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 7, 2025 |
About CTLT
Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products. The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products. Its Oral Techn... [Read more]
Financial Performance
In 2013, Catalent's revenue was $1.80 billion, an increase of 6.22% compared to the previous year's $1.69 billion. Losses were -$46.70 million, 15.6% more than in 2012.
Financial StatementsNews
Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent's network.
Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing
TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling t...
Cartherics and Catalent Expand Commercial License Agreement
MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian canc...
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.
Catalent and S.Biomedics Announce Partnership to Develop and Manufacture TED‑A9
TAMPA, Fla. & SEOUL, South Korea--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics' allogeneic plur...
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies.
Catalent's SMARTag® ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego
TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc. presented new advancements in its SMARTag® antibody-drug conjugate (ADC) technology at the 16th World ADC San Diego conference.
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscor...
Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More
Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India, a...
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director.
Catalent Announces New Board Appointments
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Mari...
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said...
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) wi...
Novo Holdings completes $16.5 bln takeover of Catalent
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfill...
Novo Holdings Completes Acquisition of Catalent
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (...
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transacti...
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of...
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Ho...
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation h...
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Ho...
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matt...
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the f...